These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 24817601

  • 1. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA, Rezaee S, Ghavamzadeh A, Alimoghaddam K, Dinan NM, Rouini MR.
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 3. Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase.
    Sharma SK, Kumar S, Vijayakumar AR, Seth T, Mishra P, Mahapatra M, Sazawal S, Velpandian T, Saxena R.
    J Cancer Res Ther; 2014 Jan; 10(2):305-8. PubMed ID: 25022382
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E, Žakelj S, Trontelj J, Pajič T, Preložnik Zupan I, Černelč P, Ostanek B, Marc J, Kristl A.
    Eur J Pharm Sci; 2013 Sep 27; 50(1):123-9. PubMed ID: 23643738
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
    Bouchet S, Titier K, Moore N, Lassalle R, Ambrosino B, Poulette S, Schuld P, Belanger C, Mahon FX, Molimard M.
    Fundam Clin Pharmacol; 2013 Dec 27; 27(6):690-7. PubMed ID: 23113675
    [Abstract] [Full Text] [Related]

  • 6. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
    Gotta V, Bouchet S, Widmer N, Schuld P, Decosterd LA, Buclin T, Mahon FX, Csajka C, Molimard M.
    Leuk Res; 2014 Jul 27; 38(7):764-72. PubMed ID: 24844604
    [Abstract] [Full Text] [Related]

  • 7. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
    De Francia S, DʼAvolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G.
    Ther Drug Monit; 2014 Jun 27; 36(3):410-2. PubMed ID: 24342895
    [Abstract] [Full Text] [Related]

  • 8. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
    Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM.
    Eur J Clin Pharmacol; 2013 Apr 27; 69(4):813-23. PubMed ID: 23052406
    [Abstract] [Full Text] [Related]

  • 9. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
    Ashariati A, Ugroseno S.
    Acta Med Indones; 2013 Apr 27; 45(2):107-13. PubMed ID: 23770790
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
    Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A, IRIS Study Group.
    Br J Clin Pharmacol; 2005 Jul 27; 60(1):35-44. PubMed ID: 15963092
    [Abstract] [Full Text] [Related]

  • 11. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
    Dybko J, Haus O, Jazwiec B, Urbaniak J, Wozniak M, Kaczmar-Dybko A, Urbaniak-Kujda D, Kapelko-Slowik K, Kuliczkowski K.
    Acta Haematol; 2014 Jul 27; 132(2):166-71. PubMed ID: 24577437
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
    Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, Leoncini-Franscini L, Baerlocher GM, Duchosal MA, Csajka C, Buclin T.
    Cancer Chemother Pharmacol; 2014 Dec 27; 74(6):1307-19. PubMed ID: 25297989
    [Abstract] [Full Text] [Related]

  • 13. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
    Dai G, Pfister M, Blackwood-Chirchir A, Roy A.
    J Clin Pharmacol; 2008 Nov 27; 48(11):1254-69. PubMed ID: 18779376
    [Abstract] [Full Text] [Related]

  • 14. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O, Chan JY, Lin K, Heng CC, Chowbay B.
    PLoS One; 2012 Nov 27; 7(12):e51771. PubMed ID: 23272163
    [Abstract] [Full Text] [Related]

  • 15. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M, Cannella L, Stefanizzi C, Latagliata R, Nanni M, Diverio D, Santopietro M, Federico V, Alimena G.
    Hematol Oncol; 2010 Jun 27; 28(2):89-92. PubMed ID: 19728398
    [Abstract] [Full Text] [Related]

  • 16. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
    J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422
    [Abstract] [Full Text] [Related]

  • 17. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
    Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY.
    Leuk Lymphoma; 2011 Jun 20; 52(6):1024-9. PubMed ID: 21463107
    [Abstract] [Full Text] [Related]

  • 18. Bioequivalence of a single 400-mg dose of imatinib 100-mg oral tablets and a 400-mg tablet in healthy adult Korean volunteers.
    Lee HW, Seong SJ, Park SM, Lee J, Gwon MR, Kim HJ, Lim SM, Lim MS, Kim W, Yang DH, Yoon YR.
    Int J Clin Pharmacol Ther; 2015 Jun 20; 53(6):480-7. PubMed ID: 25881751
    [Abstract] [Full Text] [Related]

  • 19. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
    Racil Z, Razga F, Klamova H, Voglova J, Belohlavkova P, Malaskova L, Potesil D, Muzik J, Zackova D, Polakova KM, Zdrahal Z, Malakova J, Suttnar J, Dyr J, Mayer J.
    Hematol Oncol; 2014 Jun 20; 32(2):87-93. PubMed ID: 23963760
    [Abstract] [Full Text] [Related]

  • 20. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
    Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y.
    Haematologica; 2012 May 20; 97(5):731-8. PubMed ID: 22315495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.